UK in sickle cell, thalassaemia screening drive:
This article was originally published in Clinica
Executive Summary
The UK NHS will launch sickle cell and thalassaemia screening programmes in July. Sickle cell affects some 1 in 2,400 births - around 300 a year in England. There are an estimated 12,500 cases with this serious blood disorder. The prevalence on thalassaemia is lower (at around 700 in England), but there has been a 45% combined increase in the two diseases between 1991 and 2001, says the NHS Sickle Cell and Thalassaemia Programme. Testing for thalassaemia will be performed as part of the programme for phenylketonuria and congenital hypothyroidism, in the form of a "heel-prick" or dried bloodspot test. Both programmes are being launched in Birmingham, and are aimed particularly at the communities with higher risk of the disease. They are due to be fully rolled out by March 2006.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.